Evidence map›Paper›PMID 32710998›Full record

SynthesisDiabetes research and clinical practice2020

Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: A meta-analysis.

Li Guo, Zumin Shi, Ya Zhang, Cuicui Wang, Nayla Cristina Do Vale Moreira, Hui Zuo, Akhtar Hussain

Open access · bronzeAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Diabetes research and clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 4 pooled it
2.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 4 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 5 countries.

Li GuoSoochow University Hospital, Soochow University, Suzhou, China.
Zumin ShiDepartment of Human Nutrition, College of Health Sciences, QU Health, Qatar University, Qatar.
Ya ZhangSchool of Public Health, Medical College of Soochow University, Suzhou, China.
Cuicui WangSchool of Public Health, Medical College of Soochow University, Suzhou, China.
Nayla Cristina Do Vale MoreiraInstitute of Health and Society, Department of Community Medicine and Global Health, University of Oslo, Norway; Faculty of Medicine, Federal University of Ceará (FAMED-UFC), Brazil.
Hui ZuoSchool of Public Health, Medical College of Soochow University, Suzhou, China. Electronic address: zuohui@suda.edu.cn.
Akhtar HussainFaculty of Medicine, Federal University of Ceará (FAMED-UFC), Brazil; Faculty of Health Sciences, NORD University, Bodø, Norway; International Diabetes Federation. 166 Chaussee de La Hulpe B-1170, Brussels, Belgium.
Soochow University · CNQatar University · QAUniversidade Federal do Ceará · BRUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsDiabetes mellitus has been reported to be one of the most prevalent comorbidity in patients with Coronavirus Disease 2019 (COVID-19). We aimed to assess the association of comorbid diabetes with COVID-19 severity or mortality in China.

methodsWe performed a systematic literature search from six electronic databases on diabetes and COVID-19. The outcome of interest was disease severity or mortality. Heterogeneity among the studies was assessed by the Cochran Q test and the I

resultsNine studies from different provinces/cities were identified according to the predefined inclusion and exclusion criteria. There were a total of 1070 patients with diabetes, out of the 8807 COVID-19 cases. The majority of the cases were derived from Hubei Province. A low degree of heterogeneity in the risk estimates was observed in the included studies. Meta-analysis showed that there was a significant association of preexisting diabetes with disease severity or death. The pooled RR was 2.96 (95% CI: 2.31-3.79; p < 0.001). Sensitivity analysis demonstrated no significant changes in the pooled estimates.

conclusionsComorbid diabetes was associated with an increased risk of disease severity or death in Chinese COVID-19 patients.

Indexed as

BetacoronavirusChinaComorbidityCoronavirus InfectionsCOVID-19Diabetes ComplicationsDiabetes MellitusHumansPandemicsPneumonia, ViralPrevalencePrognosisSARS-CoV-2Severity of Illness IndexSurvival RateComorbidityCOVID-19DeathDiabetesSeverity

Identifiers

PMID32710998
PMCPMC7375287
OpenAlexW3044321755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.